Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Illini Oliver, Hund Anna-Carina, Kopp Hans-Georg, Moskovitz Mor, Mountzios Giannis, Brueckl Wolfgang M, Früh Martin, Leßmann Marie-Elisabeth, Christopoulos Petros, Stenzinger Albrecht, Thomas Michael, Gillis Roni, Peled Nir, Acker Fabian, Addeo Alfredo, Charpidou Andriani, Grohé Christian, Hummel Horst-Dieter, Mauti Laetitia, Rothschild Sacha I, Schmid Sabine, Schumann Christian, Urban Damien, Wurm Robert, Ekman Simon, Skribek Marcus, Glanemann Franziska, Wiesweg Marcel, Ackermann Christoph Jakob, Agelaki Sofia, Hoffknecht Petra, Jakopović Marko, Kern Jens, König David, Kostenzer Katharina, Kropf-Sanchen Cornelia, Laack Eckart, Lang David, Nagl Laurenz, Pall Georg, Reck Martin, Kian Waleed, Allemann Anna T, Alt Jürgen, Araújo David, Bohnenberger Hanibal, Bokas Alexandros, Fabikan Hannah, Julie Krainer-Jacobs, Weinlinger Christoph, Johannes de Langen Adrianus, Fergadis Evangelos Georgios, Fischer Rieke, Fountzilas Elena, Froesch Patrizia, Frost Nikolaj, Griesinger Frank, Jordan Franziska, Karanikiotis Charisios, Kiesewetter Barbara, Korantzis Ippokratis, Machado Andrea Lopes, Economopoulou Panagiota, Pilz Arnold, Reimann Patrick, Rittmeyer Achim, Saad Akram, Samitas Konstantinos, Schulmann Karsten, Shah Riyaz, Stratmann Jan Alexander, Taghizadeh Hossein, Tammoscheit Kai, Tufman Amanda, Weber Jan-Phillip, Wöll Ewald, Valipour Arschang, Overbeck Tobias R, Hochmair Maximilian J
Аннотация
METHODS: We conducted a retrospective, multinational cohort study of patients with advanced HER2-mutant NSCLC treated with T-DXd outside clinical trials between August 2021 and January 2025 across 68 centers in Europe and Israel. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), intracranial efficacy, and safety.
RESULTS: Among 168 patients (median age 62 y; 59% female; 56% never-smokers), the ORR was 54.8% (95% confidence interval [CI]: 46.9-62.4) and disease control rate was 88.7% (95% CI: 82.9-93.1). Median PFS was 7.2 months (95% CI: 6.2-9.7) and median OS was 18.3 months (95% CI: 13.3-24.8). Treatment-naive patients (n = 18) achieved an ORR of 72.2% (95% CI: 46.5-90.3) and a median OS of 22.1 months (95% CI: 10.0-not evaluable). Patients with measurable brain metastases (n = 27) had an intracranial ORR of 74.1% (95% CI: 53.7-88.9), including 25.9% complete responses. Grade 3 or higher treatment-related adverse events occurred in 32% of patients. Interstitial lung disease/pneumonitis occurred in 14% (four fatal cases) of patients, without consistent predictors.
CONCLUSIONS: In the largest real-world cohort reported to date, T-DXd demonstrated robust systemic and intracranial activity in HER2-mutant NSCLC, including treatment-naive patients and those with active brain metastases who were largely excluded from prior studies. Toxicity was consistent with previous reports, with interstitial lung disease remaining the main safety concern. These findings support integration of HER2-targeted therapies into evolving treatment algorithms.